A microarray is refer as a tiny, bio-compatible silicon chip which is capable of rapid identification and also precise multiplexed analysis of nucleic acids (DNA/RNA). In developed countries, presently DNA Microarray industry is generally at a more advanced level. A microarray is a known as a laboratory tool which is been used to detect the thousands of expression of genes at the same time. Microarray provides accuracy and precision in disease diagnosis and drug discovery which is driving the market, while some of the factors like high cost associated with array instrument and lack of expertise to operate microarray technology is threatening the market.
- Provides Accuracy and Precision in Disease Diagnosis and Drug Discovery
- Emphasizing on Customize Treatments for Certain Deadly Diseases such as Cancer
- High Cost Associated With Array Instrument
- Lack of Expertise to Operate Microarray Technology
The key Players profiled in the report are Thermo Fischer Scientific (United States), Agilent Technologies (United States), Merck (United States), Illumina Inc. (United States), Phalanx Biotech (Taiwan), Biometrix Technology (Korea), Perkin Elmer (United States), Applied Microarrays (United States), Array It Corporation (United States) and TAKARA BIO INC. (Japan). Additionally, other players that are part of this comprehensive study are BioGenex (United States), LC Sciences (United States), US Biomax (United States), AXO Science (France) and Qiagen (Germany).